

# Rick Greupink

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8425827/publications.pdf>

Version: 2024-02-01

54  
papers

1,352  
citations

257450

24  
h-index

361022

35  
g-index

56  
all docs

56  
docs citations

56  
times ranked

1919  
citing authors

#	ARTICLE	IF	CITATIONS
1	Prediction of Moxifloxacin Concentrations in Tuberculosis Patient Populations by Physiologically Based Pharmacokinetic Modeling. <i>Journal of Clinical Pharmacology</i> , 2022, 62, 385-396.	2.0	4
2	Effects of tumor necrosis factor on undifferentiated and syncytialised placental choriocarcinoma BeWo cells. <i>Toxicology in Vitro</i> , 2022, 80, 105327.	2.4	0
3	Ex vivo dual perfusion of an isolated human placenta cotyledon: Towards protocol standardization and improved inter-centre comparability. <i>Placenta</i> , 2022, 126, 83-89.	1.5	7
4	Non-clinical considerations for supporting accelerated inclusion of pregnant women in pre-clinical trials with anti-HIV agents. <i>Journal of the International AIDS Society</i> , 2022, 25, .	3.0	4
5	Placental disposition of eculizumab, C5 and C5-eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 2128-2131.	2.4	6
6	Toxicity of anticancer drugs in human placental tissue explants and trophoblast cell lines. <i>Archives of Toxicology</i> , 2021, 95, 557-571.	4.2	19
7	Transfer of uremic solutes across the human term placenta: An ex vivo study in the dual-side perfused cotyledon. <i>Placenta</i> , 2021, 104, 220-231.	1.5	3
8	Assessment of Maternal and Fetal Dolutegravir Exposure by Integrating Ex Vivo Placental Perfusion Data and Physiologically-Based Pharmacokinetic Modeling. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 107, 1352-1361.	4.7	30
9	Transfer of daclatasvir and sofosbuvir's main metabolite, GS-331007, across the human placenta ex vivo. <i>American Journal of Obstetrics and Gynecology</i> , 2020, 223, 941-943.	1.3	3
10	Assessment of Placental Disposition of Infliximab and Etanercept in Women With Autoimmune Diseases and in the Ex Vivo Perfused Placenta. <i>Clinical Pharmacology and Therapeutics</i> , 2020, 108, 99-106.	4.7	18
11	Impact of gastrointestinal physiology on drug absorption in special populations – An UNGAP review. <i>European Journal of Pharmaceutical Sciences</i> , 2020, 147, 105280.	4.0	142
12	A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 650-662.	6.1	35
13	Pharmacokinetics of HIV-Integrase Inhibitors During Pregnancy: Mechanisms, Clinical Implications and Knowledge Gaps. <i>Clinical Pharmacokinetics</i> , 2019, 58, 309-323.	3.5	41
14	Review article: direct-acting antivirals for the treatment of HCV during pregnancy and lactation – implications for maternal dosing, foetal exposure, and safety for mother and child. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 738-750.	3.7	35
15	Differential effects of psychoactive substances on human wildtype and polymorphic T356M dopamine transporters (DAT). <i>Toxicology</i> , 2019, 422, 69-75.	4.2	10
16	Evaluating darunavir/ritonavir dosing regimens for HIV-positive pregnant women using semi-mechanistic pharmacokinetic modelling. <i>Journal of Antimicrobial Chemotherapy</i> , 2019, 74, 1348-1356.	3.0	8
17	Uremic solutes modulate hepatic bile acid handling and induce mitochondrial toxicity. <i>Toxicology in Vitro</i> , 2019, 56, 52-61.	2.4	22
18	Placental disposition of the immunosuppressive drug tacrolimus in renal transplant recipients and in ex vivo perfused placental tissue. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 119, 244-248.	4.0	20

#	ARTICLE	IF	CITATIONS
19	Microbial Glucuronidase Inhibition Reduces Severity of Diclofenac-Induced Anastomotic Leak in Rats. <i>Surgical Infections</i> , 2018, 19, 417-423.	1.4	18
20	Drug Dosing in Pregnant Women: Challenges and Opportunities in Using Physiologically Based Pharmacokinetic Modeling and Simulations. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2018, 7, 103-110.	2.5	51
21	Development of a mechanistic biokinetic model for hepatic bile acid handling to predict possible cholestatic effects of drugs. <i>European Journal of Pharmaceutical Sciences</i> , 2018, 115, 175-184.	4.0	12
22	A Mechanism-Based Population Pharmacokinetic Analysis Assessing the Feasibility of Efavirenz Dose Reduction to 400Âmg in Pregnant Women. <i>Clinical Pharmacokinetics</i> , 2018, 57, 1421-1433.	3.5	6
23	Prediction of Fetal Darunavir Exposure by Integrating Human Ex-Vivo Placental Transfer and Physiologically Based Pharmacokinetic Modeling. <i>Clinical Pharmacokinetics</i> , 2018, 57, 705-716.	3.5	43
24	Experimental study of diclofenac and its biliary metabolites on anastomotic healing. <i>BJS Open</i> , 2018, 2, 220-228.	1.7	1
25	Rat precision-cut liver slices predict drug-induced cholestatic injury. <i>Archives of Toxicology</i> , 2017, 91, 3403-3413.	4.2	14
26	Editorâ€™s Highlight: Placental Disposition and Effects of Crizotinib: An Ex Vivo Study in the Isolated Dual-Side Perfused Human Cotyledon. <i>Toxicological Sciences</i> , 2017, 157, 500-509.	3.1	19
27	Free dug concentrations in pregnancy: Bound to measure unbound?. <i>British Journal of Clinical Pharmacology</i> , 2017, 83, 2595-2598.	2.4	22
28	Therapeutic effects of the mitochondrial ROS-redox modulator KH176 in a mammalian model of Leigh Disease. <i>Scientific Reports</i> , 2017, 7, 11733.	3.3	33
29	First reported use of elvitegravir and cobicistat during pregnancy. <i>Aids</i> , 2016, 30, 807-808.	2.2	20
30	Development of a mechanistic biokinetic model describing hepatic bile acid handling to predict possible cholestatic effects of drugs. <i>Toxicology Letters</i> , 2016, 258, S47.	0.8	0
31	Substantially lowered dolutegravir exposure in a treatment-experienced perinatally HIV-1-infected pregnant woman. <i>Aids</i> , 2016, 30, 1999-2001.	2.2	10
32	Placental transfer of the HIV integrase inhibitor dolutegravir in an <i>ex vivo</i> human cotyledon perfusion model. <i>Journal of Antimicrobial Chemotherapy</i> , 2016, 71, 480-483.	3.0	34
33	Physiologically Based Modelling of Darunavir/Ritonavir Pharmacokinetics During Pregnancy. <i>Clinical Pharmacokinetics</i> , 2016, 55, 381-396.	3.5	40
34	Convallatoxin: A new P-glycoprotein substrate. <i>European Journal of Pharmacology</i> , 2014, 744, 18-27.	3.5	12
35	<i>In Silico</i> Identification and <i>In Vitro</i> Validation of Potential Cholestatic Compounds through 3D Ligand-Based Pharmacophore Modeling of BSEP Inhibitors. <i>Chemical Research in Toxicology</i> , 2014, 27, 873-881.	3.3	28
36	Interaction of Digitalis-Like Compounds with Liver Uptake Transporters NTCP, OATP1B1, and OATP1B3. <i>Molecular Pharmaceutics</i> , 2014, 11, 1844-1855.	4.6	32

#	ARTICLE	IF	CITATIONS
37	Semi-mechanistic physiologically-based pharmacokinetic modeling of clinical glibenclamide pharmacokinetics and drug-drug-interactions. <i>European Journal of Pharmaceutical Sciences</i> , 2013, 49, 819-828.	4.0	19
38	Interaction of immunosuppressive drugs with human organic anion transporter (OAT) 1 and OAT3, and multidrug resistance-associated protein (MRP) 2 and MRP4. <i>Translational Research</i> , 2013, 162, 398-409.	5.0	61
39	Drug-Drug Interactions between Rosuvastatin and Oral Antidiabetic Drugs Occurring at the Level of OATP1B1. <i>Drug Metabolism and Disposition</i> , 2013, 41, 592-601.	3.3	56
40	Pharmacological considerations on the use of antiretrovirals in pregnancy. <i>Current Opinion in Infectious Diseases</i> , 2013, 26, 575-588.	3.1	29
41	Interaction of Digitalis-Like Compounds with P-Glycoprotein. <i>Toxicological Sciences</i> , 2013, 131, 502-511.	3.1	27
42	In Silico Identification of Potential Cholestasis-Inducing Agents via Modeling of Na <sup>+</sup> -Dependent Taurocholate Cotransporting Polypeptide Substrate Specificity. <i>Toxicological Sciences</i> , 2012, 129, 35-48.	3.1	29
43	Exploiting Transport Activity of P-Glycoprotein at the Blood-Brain Barrier for the Development of Peripheral Cannabinoid Type 1 Receptor Antagonists. <i>Molecular Pharmaceutics</i> , 2012, 9, 1351-1360.	4.6	17
44	Interaction of fluvastatin with the liver-specific Na <sup>+</sup> -dependent taurocholate cotransporting polypeptide (NTCP). <i>European Journal of Pharmaceutical Sciences</i> , 2011, 44, 487-496.	4.0	40
45	Targeting fibrosis with selective drug carriers. <i>Arab Journal of Gastroenterology</i> , 2010, 10, S27-S29.	0.9	0
46	Reprint of: Targeting fibrosis with selective drug carriers. <i>Arab Journal of Gastroenterology</i> , 2010, 11, 63-65.	0.9	0
47	Evaluation of a <sup>99m</sup> Tc-Labeled AnnexinA5 Variant for Non-invasive SPECT Imaging of Cell Death in Liver, Spleen and Prostate. <i>Pharmaceutical Research</i> , 2009, 26, 2647-2656.	3.5	13
48	Pharmacokinetics of a hepatic stellate cell-targeted doxorubicin construct in bile duct-ligated rats. <i>Biochemical Pharmacology</i> , 2007, 73, 1455-1462.	4.4	9
49	Targeting 15d-Prostaglandin J2 to Hepatic Stellate Cells: Two Options Evaluated. <i>Pharmaceutical Research</i> , 2007, 24, 566-574.	3.5	42
50	Mannose-6-Phosphate/Insulin-Like Growth Factor-II Receptors may Represent a Target for the Selective Delivery of Mycophenolic Acid to Fibrogenic Cells. <i>Pharmaceutical Research</i> , 2006, 23, 1827-1834.	3.5	33
51	Selective targeting of pentoxifylline to hepatic stellate cells using a novel platinum-based linker technology. <i>Journal of Controlled Release</i> , 2006, 111, 193-203.	9.9	50
52	The Antiproliferative Drug Doxorubicin Inhibits Liver Fibrosis in Bile Duct-Ligated Rats and Can Be Selectively Delivered to Hepatic Stellate Cells in Vivo. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2006, 317, 514-521.	2.5	53
53	Studies on the targeted delivery of the antifibrogenic compound mycophenolic acid to the hepatic stellate cell. <i>Journal of Hepatology</i> , 2005, 43, 884-892.	3.7	40
54	POTENTIALS AND LIMITATIONS OF THE LOW-MOLECULAR-WEIGHT PROTEIN LYSOZYME AS A CARRIER FOR RENAL DRUG TARGETING. <i>Renal Failure</i> , 2001, 23, 397-409.	2.1	29